NIDA CENTER GRANT CONSOLIDATED PROGRAM AND REVIEW GUIDELINES

Release Date:  October 8, 1998

P.T.

National Institute on Drug Abuse

PURPOSE

The purpose of this notice is to inform the research community that the
National Institute on Drug Abuse (NIDA) has clarified, amended, and
consolidated program and review guidelines for its centers program.  This
notice of Research Center Grant Consolidated Program and Review Guidelines
will replace guidelines issued in the NIH Guide, Vol. 24, No. 33, September
22, 1995; those issued in Vol. 25, No. 4, February 16, 1996; and those issued
in Vol. 25, No. 12, April 19, 1996.

NIDA provides support for research center grants to foster a synergistic
approach to drug abuse and addiction research and to enable studies that would
not occur without the climate, facilities and research resources that a
research center can uniquely provide.  NIDA centers must have two sets of
essential and defining qualities.  The first of these is the highest caliber
of scientific work.  The second set relates to the particular characteristics
of research centers.  This set of center-specific characteristics emerges from
the confluence of thematic integration, synergy, and multidisciplinary
involvement.  A NIDA center is expected to enable a level of achievement that
exceeds that expected on the basis of "the sum of its parts".  Center support
should be essential to the achievement of work that is proposed.  The
guidelines provide further details on the purpose of NIDA's centers program, 
characteristics of NIDA centers, eligibility criteria, application procedures,
review criteria and procedures, and contacts for further information.

Applications will be accepted on an ongoing basis.  The receipt dates for all
unsolicited center applications, whether new, competing renewal, or revised,
are February 1, June 1, and October 1.  An applicant requesting $500,000 or
more in direct costs for any year of a center is required to obtain agreement
from the Institute program staff that the Institute is willing to accept the
application for review and possible funding.  The name of the program contact
should be indicated in a cover letter submitted with the application. 
Applications that do not identify a program contact will be returned to the
applicant without review.

These guidelines are effective with applications submitted for the February 1,
1999, receipt date.  With the issuance of these guidelines, NIDA will no
longer accept applications in response to the previous NIDA Research Center
Program Guidelines, published in the NIH Guide, Vol. 24, No. 33, September 22,
1995.  Note that under these new guidelines NIDA will no longer accept P20
applications in its centers program.

INQUIRIES

The Research Center Grant Consolidated Program and Review Guidelines are
available on NIDA's home page (http://www.nida.nih.gov/) and may be obtained
from:

National Institute on Drug Abuse
Office of Extramural Program Review
5600 Fishers Lane, Room 10-42
Rockville, MD 20857
Telephone:  (301) 443-2755
Email:  jp86z@nih.gov

Starting in February 1999, mail for NIDA should be sent to:

National Institute on Drug Abuse
Office of Extramural Program Review
6001 Executive Boulevard, Room 3N-3158, MSC 9547
Bethesda, MD  20892-9547
Bethesda, MD  20852 (for express/courier service)

Applications submitted under these guidelines must be sent to the Center for
Scientific Review at the address listed in the application form PHS-398.

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.